Good
Partially Aligned
Patient Risk:
Low
Summary
The response’s route/contraindication framing is consistent with the provided label excerpts, but the provided AI claims also include indication/application language not evaluated against the supplied label content, and no explicit evaluation of contraindications/warnings was included for those claims.
Category Scores
Accurate Statements
Visipaque 270 is iodixanol, a non-ionic iodinated X-ray contrast medium.
Not supported by the supplied excerpts (only contraindications/route/warnings were provided). No direct label text in the prompt confirms non-ionic/isotonic/water-soluble identity for this specific statement.
Visipaque 270 is used to enhance visibility of blood vessels and organs during imaging procedures such as CT angiography and other contrast-enhanced radiology exams.
Not supported by the supplied excerpts (no indication/usage section provided in the prompt).
Unsupported Statements
Visipaque 270 is used to enhance visibility of blood vessels and organs during imaging procedures such as CT angiography and other contrast-enhanced radiology exams.
The provided label excerpts include only Contraindications (4), Warnings/Precautions (5.1), and Dosage/Administration (2.1). No indication/usage text was included to verify this claim.
Visipaque 270 is iodixanol, a non-ionic iodinated X-ray contrast medium.
The provided label excerpts do not include the composition/class description needed to confirm 'non-ionic' and 'iodixanol' wording as stated.
Contradictions
Important Omissions
Explicitly stating the label restriction and contraindication for intrathecal use (and the warning that inadvertent intrathecal administration can cause death and severe neurologic/systemic outcomes).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The user-provided AI claims focus on general product description and imaging use, but the provided label excerpts emphasize a critical route restriction/contraindication for intrathecal use. Because the response did not include these explicit safety points, the label alignment for safety-critical content is reduced.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Key label safety information (intravascular-only and contraindication for intrathecal use, including severe outcomes from inadvertent intrathecal administration) was not present in the AI claims to be evaluated against the supplied excerpts.
Suggested Improvement
Include explicit label-aligned route restriction: 'for intravascular use only' and 'contraindicated for intrathecal use,' and (if addressing warnings) mention that inadvertent intrathecal administration can cause death and severe neurologic/systemic outcomes.